SPY443.91+0.73 0.16%
DIA347.87+0.31 0.09%
IXIC15,047.70-4.55 -0.03%

BRIEF-Mersana Therapeutics To Provide Update On Progress Of Its UpRi Clinical Development Strategy And Report Interim Data From Ovarian Cancer Expansion Cohort Of UpRi Phase I Study

reuters.com · 09/01/2021 08:37
BRIEF-Mersana Therapeutics To Provide Update On Progress Of Its UpRi Clinical Development Strategy And Report Interim Data From Ovarian Cancer Expansion Cohort Of UpRi Phase I Study

- Mersana Therapeutics Inc MRSN:

  • MERSANA THERAPEUTICS TO PROVIDE UPDATE ON THE PROGRESS OF ITS UPRI CLINICAL DEVELOPMENT STRATEGY AND REPORT INTERIM DATA FROM THE OVARIAN CANCER EXPANSION COHORT OF THE UPRI PHASE I STUDY

Source text for Eikon: ID:nGNX6FGtcG

Further company coverage: MRSN


((Reuters.Briefs@thomsonreuters.com;))